Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Cadroy, J. Bossavy, C. Thalamas, L. Sagnard, K. Sakariassen, B. Boneu (2000)
Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans.Circulation, 101 24
J. Tcheng, D. Kandzari, C. Grines, D. Cox, M. Effron, Eulogio García, J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, M. Fahy, A. Lansky, R. Mehran, G. Stone (2003)
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) TrialCirculation: Journal of the American Heart Association, 108
Franz‐Josef Neumann, A. Kastrati, C. Schmitt, R. Blasini, M. Hadamitzky, J. Mehilli, M. Gawaz, M. Schleef, M. Seyfarth, J. Dirschinger, A. Schömig (2000)
Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.Journal of the American College of Cardiology, 35 4
P. Gurbel, C. O'connor, C. Cummings, V. Serebruany (1999)
Clopidogrel: the future choice for preventing platelet activation during coronary stenting?Pharmacological research, 40 2
S. Silber, P. Albertsson, F. Avilés, P. Camici, A. Colombo, C. Hamm, E. Jørgensen, J. Marco, J. Nordrehaug, W. Rużyłło, P. Urban, G. Stone, W. Wijns (2005)
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.European heart journal, 26 8
P. Gurbel, C. Cummings, C. Bell, A. Alford, A. Meister, V. Serebruany (2003)
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.American heart journal, 145 2
M. Rosove (2004)
Platelet glycoprotein IIb/IIIa inhibitors.Best practice & research. Clinical haematology, 17 1
P. Gurbel, A. Malinin, K. Callahan, V. Serebruany, C. O'connor (2002)
Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation.The American journal of cardiology, 90 3
David Lee, N. Herity, B. Hiatt, W. Fearon, M. Rezaee, A. Carter, Michelle Huston, D. Schreiber, Peter Dibattiste, A. Yeung (2003)
Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot TrialCirculation: Journal of the American Heart Association, 107
N. Hézard, D. Metz, P. Nazeyrollas, P. Nguyên, G. Simon, S. Daliphard, C. Droullé, J. Elaerts, G. Potron (1999)
Free and Total Platelet Glycoprotein IIb/IIIa Measurement in Whole Blood by Quantitative Flow Cytometry during and after Infusion of c7E3 Fab in Patients Undergoing PTCAThrombosis and Haemostasis, 81
H. Caplain, F. Donat, C. Gaud, J. Necciari (1999)
Pharmacokinetics of clopidogrel.Seminars in thrombosis and hemostasis, 25 Suppl 2
A. Matzdorff, G. Kühnel, B. Kemkes‐Matthes, H. Pralle, R. Voss, J. Fareed (2000)
Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.The Journal of laboratory and clinical medicine, 135 3
(1997)
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplastyCirculation, 96
S. Brener, L. Barr, J. Burchenal, S. Katz, B. George, A. Jones, E. Cohen, Phillip Gainey, H. White, H. Cheek, J. Moses, D. Moliterno, M. Effron, E. Topol (1998)
Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial InfarctionCirculation, 98
T. Investigators (1997)
Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.Circulation, 96 5
A. Lepäntalo, K. Virtanen, J. Heikkilä, U. Wartiovaara, R. Lassila (2004)
Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.European heart journal, 25 6
João Araújo, H. Veloso, Joyce Paiva, Mohamed Filho, A. Paola (2004)
Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.American heart journal, 148 6
H. Dieker, M. Brouwer, F. Verheugt (2005)
ESC guidelines for percutaneous coronary interventions.European heart journal, 26 22
Am J Cardiovasc Drugs 2007; 7 (6): 433-439 ORIGINAL RESEARCH ARTICLE 1175-3277/07/0006-0433/$44.95/0 © 2007 Adis Data Information BV. All rights reserved. Expression of Platelet Surface Receptors and Early Changes in Platelet Function in Patients with STEMI Treated with Abciximab and Clopidogrel versus Clopidogrel Alone Anna Konopka, Justyna Spychalska, Dariusz Sitkiewicz, Ewa Zdebska , Iwona Pilichowska, Walerian Piotrowski and Janina Stepinska Institute of Cardiology and Institute of Haematology and Blood Transfusion in Warsaw, Warsaw, Poland Abstract Background: Platelets play a crucial role in the pathogenesis of acute coronary syndromes (ACS). The efficacy of antiplatelet treatment is pivotal in the success of percutaneous coronary intervention (PCI) performed in patients with ACS. Objective: The aim of the study was to investigate the effects of clopidogrel with or without abciximab on the expression of platelet surface receptors and platelet function in patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI. Materials and methods: Thirty patients with STEMI were included in the study. During acute primary coronary intervention, patients received aspirin (acetylsalicylic acid) and clopidogrel in a loading dose of 300mg. Clopidogrel was the only antiplatelet therapy used by nine patients (group B). Twenty-one patients (group A) received additional abciximab. Blood samples were collected
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.